Prognostic value of preoperative neutrophil-lymphocyte ratio is superior to platelet-lymphocyte ratio for survival in patients who underwent complete resection of thymic carcinoma

Journal of Thoracic Disease

Volumn 8, Issue 7, 2016, Pages 1487-1496

  Yuan, Zu Yang ^a   Gao, Shu Geng ^a   Mu, Ju Wei ^a   Xue, Qi ^a   Mao, You Sheng ^a   Wang, Da Li ^a   Zhao, Jun ^a   Gao, Yu Shun ^a   Huang, Jin Feng ^a   He, Jie ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Neutrophil lymphocyte ratio (NLR); Platelet lymphocyte ratio (PLR); Prognosis; Thymic carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL LYMPHOCYTE RATIO; OBSERVATIONAL STUDY; OPEN SURGERY; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; RECURRENCE RISK; RETROSPECTIVE STUDY; THYMUS CANCER; TUMOR VOLUME; VIDEO ASSISTED THORACOSCOPIC SURGERY;

EID: 85034031923     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/JTD.2016.05.05     Document Type: Article

References (37)

1. Carter BW, Okumura M, Detterbeck FC, et al. Approaching the patient with an anterior mediastinal mass: a guide for radiologists. J Thorac Oncol 2014;9:S110-8
2. Greene MA, Malias MA. Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg 2003;125:434-6
3. Masaoka A. Staging system of thymoma. J Thorac Oncol 2010;5:S304-12
4. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003;76:878-84; discussion 884-5
5. Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004;59:654-64
6. Kondo K. Optimal therapy for thymoma. J Med Invest 2008;55:17-28
7. Forquer JA, Rong N, Fakiris AJ, et al. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys 2010;76:440-5
8. Rajan A, Giaccone G. Chemotherapy for thymic tumors: induction, consolidation, palliation. Thorac Surg Clin 2011;21:107-14, viii
9. Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218-30
10. Zhang H, Xia H, Zhang L, et al. Clinical significance of preoperative neutrophil-lymphocyte vs plateletlymphocyte ratio in primary operable patients with nonsmall cell lung cancer. Am J Surg 2015;210:526-35
11. Zhang WW, Liu KJ, Hu GL, et al. Preoperative platelet/ lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients. Tumour Biol 2015;36:8831-7
12. Huang GQ, Zhu GQ, Liu YL, et al. Stratified neutrophilto-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection. Oncotarget 2016;7:5429-39
13. Wong BY, Stafford ND, Green VL, et al. Prognostic value of the neutrophil-to-lymphocyte ratio in patients with laryngeal squamous cell carcinoma. Head Neck 2016;38 Suppl 1:E1903-8
14. Lian L, Xia YY, Zhou C, et al. Application of platelet/ lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer. Cancer Biomark 2015;15:899-907
15. Seong MK. Prognostic Inflammation Score in Surgical Patients with Colorectal Cancer. J Korean Med Sci 2015;30:1793-9
16. Huang J, Dahl DM, Dong L, et al. Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma. Biomed Res Int 2015;2015:891045
17. Jia W, Wu J, Jia H, et al. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. PLoS One 2015;10:e0143061
18. Inoue D, Ozaka M, Matsuyama M, et al. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan. Jpn J Clin Oncol 2015;45:61-6
19. Marx A, Chan JK, Coindre JM, et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol 2015;10:1383-95
20. Wu JX, Chen HQ, Shao LD, et al. Long-term follow-up and prognostic factors for advanced thymic carcinoma. Medicine (Baltimore) 2014;93:e324
21. Omasa M, Date H, Sozu T, et al. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database Study. Cancer 2015;121:1008-16
22. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7
23. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4:641-8
24. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014;16:717-27
25. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-63
26. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
28. Proctor MJ, Horgan PG, Talwar D, et al. Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study. Cancer 2013;119:2325-32
29. Kinoshita A, Onoda H, Imai N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer 2012;107:988-93
30. Motomura T, Shirabe K, Mano Y, et al. Neutrophillymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013;58:58-64
31. Kantola T, Klintrup K, Väyrynen JP, et al. Stagedependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer 2012;107:1729-36
32. Pan QX, Su ZJ, Zhang JH, et al. A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer. Onco Targets Ther 2015;8:1375-85
33. Graziosi L, Marino E, De Angelis V, et al. Prognostic value of preoperative neutrophils to lymphocytes ratio in patients resected for gastric cancer. Am J Surg 2015;209:333-7
34. Del Prete M, Giampieri R, Loupakis F, et al. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget 2015;6:33982-92
35. Mori K, Toiyama Y, Saigusa S, et al. Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery. Dig Dis Sci 2015;60:2477-87
36. Shimizu K, Okita R, Saisho S, et al. Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer. World J Surg Oncol 2015;13:291
37. Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007;97:1266-70